ZA200305116B - Purine derivatives as purinergic receptor antagonists. - Google Patents

Purine derivatives as purinergic receptor antagonists.

Info

Publication number: ZA200305116B
Authority: ZA; South Africa
Prior art keywords: sub; alkyl; aryl; conr; disorder
Prior art date: 2001-01-10

Application number

ZA200305116A

Other languages

English (en)

Inventor

Roger John Gillespie

Joanne Lerpiniere

Claire Elizabeth Dawson

Suneel Gaur

Robert Mark Pratt

Gemma Caroline Stratton

Scott Murray Weiss

Original Assignee

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-10

Filing date

2003-07-01

Publication date

2004-07-01

2003-07-01 Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd

2004-07-01 Publication of ZA200305116B publication Critical patent/ZA200305116B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200305116A 2001-01-10 2003-07-01 Purine derivatives as purinergic receptor antagonists. ZA200305116B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0100623.8A GB0100623D0 (en)	2001-01-10	2001-01-10	Chemical compounds IV

Publications (1)

Publication Number	Publication Date
ZA200305116B true ZA200305116B (en)	2004-07-01

Family

ID=9906570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200305116A ZA200305116B (en)	2001-01-10	2003-07-01	Purine derivatives as purinergic receptor antagonists.

Country Status (22)

Country	Link
US (2)	US7452894B2 (fr)
EP (1)	EP1349857B1 (fr)
JP (1)	JP4284069B2 (fr)
KR (1)	KR20030079945A (fr)
CN (1)	CN1617871A (fr)
AT (1)	ATE471323T1 (fr)
AU (1)	AU2002217331B2 (fr)
BR (1)	BR0206561A (fr)
CA (1)	CA2433858C (fr)
CZ (1)	CZ20031956A3 (fr)
DE (1)	DE60236719D1 (fr)
GB (1)	GB0100623D0 (fr)
HU (1)	HUP0402504A2 (fr)
IL (1)	IL156779A0 (fr)
MX (1)	MXPA03006163A (fr)
NO (1)	NO20033145L (fr)
NZ (1)	NZ527249A (fr)
PL (1)	PL363172A1 (fr)
RU (1)	RU2003124653A (fr)
WO (1)	WO2002055521A1 (fr)
YU (1)	YU55603A (fr)
ZA (1)	ZA200305116B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE364607T1 (de) *	2001-04-05	2007-07-15	Sumitomo Chemical Co	Verfahren zur produktion von 2,6- dihalogenopurinen
EP1440072A4 (fr)	2001-10-30	2005-02-02	Conforma Therapeutic Corp	Analogues de purine presentant une activite inhibitrice de hsp90
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
DE10252650A1 (de) *	2002-11-11	2004-05-27	Grünenthal GmbH	Cyclohexyl-Harnstoff-Derivate
US7129244B2 (en)	2003-09-18	2006-10-31	Conforma Therapeutics Corporation	Triazolopyrimidines and related analogs as HSP90-inhibitors
JPWO2005085210A1 (ja) *	2004-03-10	2008-01-17	小野薬品工業株式会社	ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2007035873A1 (fr) *	2005-09-21	2007-03-29	Pharmacopeia, Inc.	Dérivés de purinone pour le traitement de maladies neurodégénératives
CN1947717B (zh) *	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7989459B2 (en)	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043031A1 (fr)	2006-10-04	2008-04-10	Pharmacopeia, Inc.	Dérivés de 2-(benzimidazolyl) purine et de purinone substitués en position 6 pour immunosuppression
AR063141A1 (es)	2006-10-04	2008-12-30	Pharmacopeia Inc	Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US20090054468A1 (en) *	2007-08-23	2009-02-26	Astrazeneca Ab	New Use 938
DK2209786T3 (da)	2007-10-05	2013-06-03	Verastem Inc	Pyrimidinsubstituerede purinderivater
GB0906579D0 (en) *	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
RU2506264C2 (ru)	2009-04-03	2014-02-10	Вэрастэм, Инк.	Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
ES2690557T3 (es)	2011-06-02	2018-11-21	University Of Louisville Research Foundation, Inc.	Nanopartículas conjugadas a un agente antinucleolina
WO2012172043A1 (fr) *	2011-06-15	2012-12-20	Laboratoire Biodim	Dérivés de purine et leur utilisation comme produits pharmaceutiques pour prévenir ou traiter les infections bactériennes
US9328118B2 (en) *	2012-04-17	2016-05-03	Astellas Pharma Inc.	Nitrogen-containing bicyclic aromatic heterocyclic compound
WO2018093758A1 (fr) *	2016-11-18	2018-05-24	The Procter & Gamble Company	Compositions de traitement de tissu et procédés apportant un bénéfice
US10870816B2 (en)	2016-11-18	2020-12-22	The Procter & Gamble Company	Fabric treatment compositions having low calculated cationic charge density polymers and fabric softening actives and methods for providing a benefit
WO2019039438A1 (fr) *	2017-08-21	2019-02-28	国立大学法人三重大学	Procédé d'observation utilisant un modèle d'infarctus cérébral de mammifère non humain, et dispositif d'observation utilisant un modèle d'infarctus cérébral de mammifère non humain
CN107903274A (zh) *	2017-12-28	2018-04-13	窦玉玲	一种胺类化合物及其在抗肿瘤药物中的应用
US20220380310A1 (en) *	2019-07-01	2022-12-01	Ligang Qian	P2x7r antagonists
KR20210061202A (ko) *	2019-11-19	2021-05-27	일동제약(주)	벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
US11787775B2 (en) *	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
US11806350B2 (en)	2020-11-19	2023-11-07	Ildong Pharmaceutical Co., Ltd.	Prevention and/or treatment of CNS disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3630997A (en) *	1970-05-04	1971-12-28	Paul M Craven	Curable epoxy resin compositions and method of preparing same
US5064745A (en) *	1988-02-25	1991-11-12	Mitsubishi Paper Mills, Ltd.	Method for making lithographic printing plate
US5403932A (en) *	1988-05-25	1995-04-04	Research Corporation Technologies, Inc.	Phosphoramidates useful as antitumor agents
US5968989A (en) *	1991-12-18	1999-10-19	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
DE4330735A1 (de) *	1993-09-10	1995-03-16	Wacker Chemie Gmbh	Hydrophile Gruppen aufweisende Organopolysiloxane
US5789416B1 (en) *	1996-08-27	1999-10-05	Cv Therapeutics Inc	N6 mono heterocyclic substituted adenosine derivatives
CN1268137A (zh)	1997-07-03	2000-09-27	杜邦药品公司	治疗神经失调的咪唑并嘧啶和咪唑并吡啶
EP0975345A1 (fr) *	1997-11-26	2000-02-02	Cerebrus Pharmaceuticals Limited	(-)-mefloquine utilisee pour le blocage de recepteurs purinergiques et pour le traitement de perturbations neurodegeneratives et des mouvements
EP1054012B1 (fr)	1998-01-05	2003-06-11	Eisai Co., Ltd.	Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
JPH11279193A (ja) *	1998-03-24	1999-10-12	Akira Matsuda	アデノシン誘導体
GB9819382D0 (en) *	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9819384D0 (en) *	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds II
GB9915437D0 (en) *	1999-07-01	1999-09-01	Cerebrus Ltd	Chemical compounds III
PT1221444E (pt)	1999-07-02	2005-11-30	Eisai Co Ltd	Derivados de imidazole condensados e medicamentos para a diabetes mellitus
JP2003531187A (ja) *	2000-04-26	2003-10-21	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	サブタイプ選択的ｎｍｄａ受容体アンタゴニストとしてのシクロヘキシルアミン誘導体
US6903238B2 (en) *	2001-12-13	2005-06-07	Wyeth	Substituted indenones as estrogenic agents
US6946005B2 (en) *	2002-03-27	2005-09-20	L'oreal S.A.	Pyrrolidinyl-substituted para-phenylenediamine derivatives substituted with a cationic radical, and use of these derivatives for dyeing keratin fibers
DE10326303A1 (de) *	2003-06-11	2004-12-30	Celares Gmbh	Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
CN101103026A (zh) *	2005-01-14	2008-01-09	健亚生物科技公司	用于治疗病毒感染的吲哚衍生物
JP5190364B2 (ja) *	2005-09-09	2013-04-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	大環状ペプチドの調製の為の閉環メタセシス工程
EP1965805B1 (fr) *	2005-11-25	2009-12-02	Galapagos SAS	Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
US8143236B2 (en) *	2005-12-13	2012-03-27	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods
CN101528741A (zh) *	2006-07-20	2009-09-09	健亚生物科技公司	多环病毒抑制剂

2001
- 2001-01-10 GB GBGB0100623.8A patent/GB0100623D0/en not_active Ceased
2002
- 2002-01-10 US US10/250,941 patent/US7452894B2/en not_active Expired - Fee Related
- 2002-01-10 AT AT02729444T patent/ATE471323T1/de not_active IP Right Cessation
- 2002-01-10 BR BR0206561-4A patent/BR0206561A/pt not_active Application Discontinuation
- 2002-01-10 RU RU2003124653/04A patent/RU2003124653A/ru not_active Application Discontinuation
- 2002-01-10 DE DE60236719T patent/DE60236719D1/de not_active Expired - Lifetime
- 2002-01-10 NZ NZ527249A patent/NZ527249A/xx unknown
- 2002-01-10 HU HU0402504A patent/HUP0402504A2/hu unknown
- 2002-01-10 JP JP2002556190A patent/JP4284069B2/ja not_active Expired - Fee Related
- 2002-01-10 WO PCT/GB2002/000076 patent/WO2002055521A1/fr active IP Right Grant
- 2002-01-10 MX MXPA03006163A patent/MXPA03006163A/es unknown
- 2002-01-10 AU AU2002217331A patent/AU2002217331B2/en not_active Ceased
- 2002-01-10 CZ CZ20031956A patent/CZ20031956A3/cs unknown
- 2002-01-10 EP EP02729444A patent/EP1349857B1/fr not_active Expired - Lifetime
- 2002-01-10 CN CNA028062582A patent/CN1617871A/zh active Pending
- 2002-01-10 IL IL15677902A patent/IL156779A0/xx unknown
- 2002-01-10 PL PL02363172A patent/PL363172A1/xx not_active Application Discontinuation
- 2002-01-10 CA CA2433858A patent/CA2433858C/fr not_active Expired - Fee Related
- 2002-01-10 YU YU55603A patent/YU55603A/sh unknown
- 2002-01-10 KR KR10-2003-7009241A patent/KR20030079945A/ko not_active Application Discontinuation
2003
- 2003-07-01 ZA ZA200305116A patent/ZA200305116B/xx unknown
- 2003-07-09 NO NO20033145A patent/NO20033145L/no not_active Application Discontinuation
2006
- 2006-07-19 US US11/488,750 patent/US20060270691A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20060270691A1 (en)	2006-11-30
CN1617871A (zh)	2005-05-18
JP2004517874A (ja)	2004-06-17
EP1349857A1 (fr)	2003-10-08
RU2003124653A (ru)	2005-01-10
GB0100623D0 (en)	2001-02-21
CA2433858A1 (fr)	2002-07-18
NZ527249A (en)	2005-04-29
JP4284069B2 (ja)	2009-06-24
NO20033145D0 (no)	2003-07-09
CA2433858C (fr)	2010-12-14
ATE471323T1 (de)	2010-07-15
AU2002217331B2 (en)	2006-06-29
WO2002055521A1 (fr)	2002-07-18
KR20030079945A (ko)	2003-10-10
EP1349857B1 (fr)	2010-06-16
CZ20031956A3 (cs)	2003-11-12
BR0206561A (pt)	2004-06-22
DE60236719D1 (de)	2010-07-29
PL363172A1 (en)	2004-11-15
NO20033145L (no)	2003-09-09
HUP0402504A2 (hu)	2005-04-28
US20040102459A1 (en)	2004-05-27
US7452894B2 (en)	2008-11-18
MXPA03006163A (es)	2003-09-16
IL156779A0 (en)	2004-02-08
YU55603A (sh)	2006-05-25

Publication	Publication Date	Title
ZA200305116B (en)	2004-07-01	Purine derivatives as purinergic receptor antagonists.
DK1392312T3 (da)	2009-06-15	Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister
DE60228817D1 (de)	2008-10-23	THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN
DE60228414D1 (de)	2008-10-02	Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
MY136270A (en)	2008-09-30	Processes and intermediates for preparing anti-cancer compounds
GEP20084357B (en)	2008-04-29	Pyrimidine derivatives for the treatment of abnormal cell growth
TW200716528A (en)	2007-05-01	Cyclopropanecarboxamide derivatives
HK1068334A1 (en)	2005-04-29	Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
IL179171A0 (en)	2007-03-08	Alkyl substituted indoloquinoxalines
BRPI0409959A (pt)	2006-04-25	uso de derivados de azetidinacarboxamida em terapia
PL353646A1 (en)	2003-12-01	Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
WO2006029154A3 (fr)	2006-11-23	Nouveaux composes
CA2375671A1 (fr)	2000-12-07	Derives de 4-phenyle-pyrimidine
MXPA04005077A (es)	2004-08-19	Derivados de benzotiazol.
ES2185985T3 (es)	2003-05-01	Derivados de 4-aminoetoxiindolona como agonistas del receptor d2 de dopamina.